Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.

Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA.

Stem Cells. 2009 Sep;27(9):2353-61. doi: 10.1002/stem.156.

2.

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A.

Neoplasia. 2005 May;7(5):537-43.

3.

Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.

Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR.

Oncogene. 2005 Jun 23;24(27):4442-9. Erratum in: Oncogene. 2005 Dec 8;24(55):8216.

PMID:
15856028
5.

Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.

Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TR.

Mol Cancer Res. 2010 Apr;8(4):615-26. doi: 10.1158/1541-7786.MCR-09-0264. Epub 2010 Mar 30.

6.

EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.

Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, Neumann D, Rönnstrand L, Påhlman S.

Biochem Biophys Res Commun. 2014 Feb 28;445(1):163-9. doi: 10.1016/j.bbrc.2014.01.165. Epub 2014 Feb 3.

7.

RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.

Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, Acs G.

Am J Pathol. 2009 Apr;174(4):1504-14. doi: 10.2353/ajpath.2009.080592. Epub 2009 Mar 5.

8.

Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells.

Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C, Rocha-Zavaleta L.

Int J Cancer. 2011 Dec 1;129(11):2566-76. doi: 10.1002/ijc.25935. Epub 2011 Mar 25.

9.
10.

Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.

Larsson AM, Jirström K, Fredlund E, Nilsson S, Rydén L, Landberg G, Påhlman S.

Clin Cancer Res. 2009 Sep 1;15(17):5552-9. doi: 10.1158/1078-0432.CCR-08-3014. Epub 2009 Aug 25.

11.

The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.

Vukelic J, Dobrila-Dintinjana R, Jonjic N, Dekanic A, Ilijic V.

Med Hypotheses. 2013 Dec;81(6):1155-8. doi: 10.1016/j.mehy.2013.09.030. Epub 2013 Oct 1.

PMID:
24134826
12.

Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.

Tong W, Zhang J, Lodish HF.

Blood. 2005 Jun 15;105(12):4604-12. Epub 2005 Feb 10.

14.

Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.

Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N.

Blood. 1994 Sep 1;84(5):1501-7.

15.

Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.

Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA.

Clin Cancer Res. 2005 Jan 1;11(1):20-7.

17.

Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.

Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ.

Prostate. 2006 Feb 1;66(2):135-45.

PMID:
16161153
18.

Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells.

Ammarguellat F, Llovera M, Kelly PA, Goffin V.

Biochem Biophys Res Commun. 2001 Jun 22;284(4):1031-8.

PMID:
11409898
19.
20.

Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.

Aguilar C, Aguilar C, Lopez-Marure R, Jiménez-Sánchez A, Rocha-Zavaleta L.

Mol Med Rep. 2014 May;9(5):1895-902. doi: 10.3892/mmr.2014.2044. Epub 2014 Mar 12.

PMID:
24626629

Supplemental Content

Support Center